Cargando…
Multimodal analysis of granulocytes, monocytes, and platelets in patients with cystic fibrosis before and after Elexacaftor–Tezacaftor–Ivacaftor treatment
Cystic fibrosis (CF) is a monogenetic disease caused by an impairment of the cystic fibrosis transmembrane conductance regulator (CFTR). CF affects multiple organs and is associated with acute and chronic inflammation. In 2020, Elexacaftor–Tezacaftor–Ivacaftor (ETI) was approved to enhance and resto...
Autores principales: | Schmidt, Hanna, Höpfer, Larissa Melina, Wohlgemuth, Lisa, Knapp, Christiane Leonie, Mohamed, Adam Omar Khalaf, Stukan, Laura, Münnich, Frederik, Hüsken, Dominik, Koller, Alexander Sebastian, Stratmann, Alexander Elias Paul, Müller, Paul, Braun, Christian Karl, Fabricius, Dorit, Bode, Sebastian Felix Nepomuk, Huber-Lang, Markus, Messerer, David Alexander Christian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10347380/ https://www.ncbi.nlm.nih.gov/pubmed/37457734 http://dx.doi.org/10.3389/fimmu.2023.1180282 |
Ejemplares similares
-
Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis
Publicado: (2021) -
Impact of elexacaftor/tezacaftor/ivacaftor on depression and anxiety
in cystic fibrosis
por: Zhang, Lijia, et al.
Publicado: (2022) -
Post-approval studies with the CFTR modulators Elexacaftor-Tezacaftor—Ivacaftor
por: Tümmler, Burkhard
Publicado: (2023) -
Impact of pharmacy services on time to elexacaftor-tezacaftor-ivacaftor initiation
por: Roder, Lauren, et al.
Publicado: (2022) -
Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor/Tezacaftor/Ivacaftor therapy
por: Westhölter, Dirk, et al.
Publicado: (2023)